Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Beyond FISH: CMA detects 8p-, xq+, and y- as markers of early post-transplant progression in myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMariusz A. WasikMHMatthew HambyAYAsya Varshavsky Yanovsky

Discussion

Loading...

Member takes

Overview

Cytogenomic microarray reveals 8p- and Y- as early progression markers in myeloma patients post-autologous SCT, suggesting tailored strategies may improve outcomes.

Key Points

  • The study aims to identify cytogenetic abnormalities detected by CMA that are associated with early post-transplant progression in multiple myeloma.
  • Analyzed post-induction bone marrow samples from patients with newly diagnosed multiple myeloma who underwent autologous SCT.
  • Only included patients treated with one line of induction therapy.
  • CMA was performed using ThermoFisher CytoScan HD microarrays to detect abnormalities.
  • 202 out of 316 patients remained progression-free at 18 months, while 51 had early progressive disease.
  • CMA identified recurrent cytogenetic abnormalities, with 8p- linked to early progression at a significant rate.
  • 8p- was found almost exclusively in early progressors, suggesting its potential as a prognostic factor.

Cite This Study

Wasik et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7ebhttps://doi.org/10.1182/blood-2025-2222
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic Cytogenetic Evolution in Multiple Myeloma: Prognostic Implications from Diagnosis to First Relapse2026 · 1 citations
  2. 2P31 | PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE2026
  3. 3Dynamic changes in cytogenetic abnormalities during treatment predict long-term outcomes in multiple myeloma2025
  4. 4MYC rearrangements with immunoglobulin genes as an independent prognostic factor of progression-free survival in newly diagnosed patients2025
  5. 5Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms2025